Search clinical trials for: epoetin beta [NeoRecormon]

Total 6461 results

Groupe Francophone des Myelodysplasies

Completed

Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS) (EPO-QoL)

Myelodysplastic Syndromes

France
Leiden University Medical Center

Completed

PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation

Patients Receiving a Kidney From a Non-Heart-Beating Donor

Netherlands
Hoffmann-La Roche

Completed

A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies

Anemia

Bulgaria
Centre Hospitalier Universitaire, Amiens
Roche Pharma AG

Completed

Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney Transplant (Neo-PDGF)

Kidney Failure

France
Hoffmann-La Roche

Completed

An Observational Study of Epoetin Beta [Neorecormon] to Evaluate the Quality of Life in Patients on Dialysis With Chronic Renal Anemia

Anemia

Morocco
Hoffmann-La Roche

Completed

An Observational Study of Epoetin Beta (NeoRecormon) in Participants With Cancer Receiving Chemotherapy

Anemia

Hungary
Hoffmann-La Roche

Completed

A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia

Anemia

Italy, Spain, Sweden, Hong Kong, Greece, Ireland, United Kingdom, Portugal, Taiwan, Turkey, France, Germany, Russian Federation, Belgium, Austria, Thailand, Poland, Czech Republic, Denmark, Finland, Norway, Mexico
Hoffmann-La Roche

Completed

An Observational Study of NeoRecormon (Epoetin Beta) in Cancer Patients With Anemia (FAST)

Anemia, Neoplasms

France
Hoffmann-La Roche

Completed

A Study of Epoetin Beta (NeoRecormon) in Predialysis Patients With Renal Anemia

Anemia

Bulgaria
University Hospital, Angers

Completed

Use or Non-use of Epoetin Beta in Patients Infected by Chronic Hepatitis C

Chronic Hepatitis C

France
Charite University, Berlin, Germany

Completed

Chronic, Low Dose Erythropoetin Beta in Ischemic Cardiomyopathy (EPOHeart)

Ischemic Cardiomyopathy

Germany
Hoffmann-La Roche

Completed

A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors

Anemia

Spain
Hoffmann-La Roche

Completed

COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.

Anemia

Australia
Hoffmann-La Roche

Completed

A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy

Anemia

Italy
Hoffmann-La Roche

Completed

A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.

Anemia

Serbia
Western Galilee Hospital-Nahariya

Unknown

Prevention of Contrast Induced Nephropathy by Erythropoietin

Diabetes | Chronic Kidney Insufficiency

Israel
Hoffmann-La Roche

Completed

A Study of Epoetin Beta (NeoRecormon) in Anemic Participants With Diabetes and Chronic Renal Failure Who Are Not on Dialysis

Anemia

France
University of Copenhagen
Rigshospitalet, Denmark

Completed

Renal Effects of Erythropoietin in Humans (EPO 2012)

Renal Effects

Denmark
Hoffmann-La Roche

Completed

(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy

Anemia

Italy, Spain, Mexico, Hungary, Singapore, Greece, United Kingdom, Austria, Thailand, Germany, Poland, Russian Federation, Denmark, Brazil, Sweden, Czech Republic, Finland
Hoffmann-La Roche

Completed

A Study of NeoRecormon in Patients With Chronic Kidney Disease.

Anemia

Serbia
Hoffmann-La Roche

Terminated

A Study of NeoRecormon (Epoetin Beta) in Patients With Renal Anemia.

Anemia

Australia
Imperial College London

Completed

Predictors of Response to Iron and Erythropoietin Stimulating Agents (PRIME)

Anemia | Renal Failure Chronic
Affymax
Takeda

Completed

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis (EMERALD 2)

Anemia | Chronic Kidney Disease | Chronic Renal Failure

United States, Bulgaria, Romania, United Kingdom, Italy, Poland, France, Germany, Spain
Hoffmann-La Roche

Completed

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

Chronic Renal Anemia

Belgium, Brazil, United Kingdom, Serbia, Spain, Germany, Korea, Republic of, Turkey, Lithuania, Italy, Czechia, Argentina, Australia, Croatia, France, Greece, Israel, Malaysia, Mexico, Panama, Philippines, Poland, Russian Federation, ... and more
Rigshospitalet, Denmark
Danish Research Centre for Magnetic Resonance

Unknown

The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis (EPO-ProgMS)

Multiple Sclerosis (Primary or Secondary Progressive Phase).

Denmark
Centre Hospitalier Universitaire, Amiens
Roche Pharma AG

Completed

Correction of Anaemia and Progression of Renal Failure on Transplanted Patients

Kidney Failure | Renal Transplantation | Anaemia

France
Hoffmann-La Roche

Completed

A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy

Anemia

Italy
Huiqing Sun
Göteborg University; Zhengzhou University

Enrolling by invitation

Recombinant Human Erythropoietin Improve Neurodevelopmental Outcomes in Extremely Preterm Infants (EPO)

Developmental Disabilities
Zhengzhou University
Göteborg University; Zhengzhou Children's Hospital, China

Completed

Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage

Premature Infants

China
Hoffmann-La Roche

Completed

A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.

Anemia

France
Deutsches Herzzentrum Muenchen

Completed

Efficacy Study of Erythropoietin After Revascularization in Myocardial Infarction (REVIVAL-3) (REVIVAL-3)

Myocardial Infarction | Angioplasty, Transluminal, Percutaneous Coronary

Germany
Groupe Francophone des Myelodysplasies
Roche Pharma AG; Celgene

Completed

Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.

Myelodysplastic Syndromes

France, Monaco
Rennes University Hospital

Unknown

Effects of Intravenous Injection of Erythropoietin on Hepcidin Pharmacokinetics in Healthy Volunteers (HEPEPO)

Iron Metabolism Disorders

France
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Anemia

Belgium, Spain, United States, Sweden, Denmark, Taiwan, France, Italy, United Kingdom, New Zealand, South Africa, Hungary, Thailand, Mexico, Poland, Czech Republic, Puerto Rico, Finland, Brazil, Germany, Panama
Claude Bernard University

Unknown

Randomized Trial of Erythropoietin During Cerebral Malaria (EPOMAL)

Cerebral Malaria

Mali
China Medical University Hospital

Unknown

Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants

Retinopathy of Prematurity | Intraventricular Hemorrhage | Infant, Premature | Leukomalacia, Periventricular

Taiwan
InCROM Europe Clinical Research

Completed

Bioequivalence of a Single Subcutaneous Dose of Epoetin Beta in Healthy Japanese and Caucasian Male Subjects

Anaemia | Chronic Kidney Failure
Hoffmann-La Roche

Completed

A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Anemia

China, Hong Kong
Hoffmann-La Roche

Completed

A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia.

Anemia

China
Chugai Pharmaceutical

Completed

Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) Patients

Anemia

Japan
Chugai Pharmaceutical

Completed

Clinical Study of R744 to Predialysis Patients( Phase III, Comparative Study in Comparison With Epoetin Beta)

Predialysis Patients

Japan
Hoffmann-La Roche

Completed

A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies

Anemia

Russian Federation
Charite University, Berlin, Germany
University Hospital, Strasbourg, France; University of Zurich; Hoffmann-La Roche and other collaborators

Completed

Erythropoietin Treatment in Extremely Low Birth Weight Infants (EPO)

Anemia | Infant, Low Birth Weight

Germany
Hoffmann-La Roche

Completed

A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Anemia

France, Germany, Italy, United States, Taiwan, Canada, Puerto Rico, Spain, Thailand, Portugal, United Kingdom, Poland
Hoffmann-La Roche

Terminated

A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Anemia

United States
University Hospital, Grenoble
Roche Pharma AG

Completed

Preliminary Administration of EPO and Markers of Cardiac Ischemia Induced by CPB (EPOetCEC)

Myocardial Ischemia

France
University of Cambridge
Hoffmann-La Roche; Roche Foundation of Anemia Research (RoFAR, Switzerland)

Completed

Erythropoietin Therapy for Subarachnoid Hemorrhage

Aneurysmal Subarachnoid Hemorrhage

United Kingdom
Hoffmann-La Roche

Completed

An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant

Anemia, Kidney Transplantation

Germany
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera for the Correction of Anemia in Dialysis Patients.

Anemia

Korea, Republic of
Hamad Medical Corporation

Completed

Comparison Among Erythropoietin Stimulating Agents

Anemia of End Stage Renal Disease

Qatar

3

Subscribe